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Background: Nasal chondromesenchymal hamartoma (NCMH) is a very rare, benign tumour of the sinonasal tract
usually presenting in infants. We present a systematic review of NCMH cases alongside a case report of an adult
with asymptomatic NCMH.
Methods: A systematic review was conducted in accordance with PRISMA guidelines. A PubMed, EMBASE and manual
search through references of relevant publications was used to identify all published case-reports of NCMH. Data
was collected from each case-report on: patient demographics, laterality, size and location of NCMH, presentation,
co-morbidities, investigations, treatment and follow-up.
Results: The systematic review identified 48 patients (including ours): 33 male, 15 female. Mean age was 9.6 years
(range: 1 day–69 years) with the majority aged 1 year or younger at presentation (n = 18). Presentations included:
nasal congestion (n = 17), nasal mass (n = 15) and eye signs (n = 12). NCMH also involved the paranasal sinuses
(n = 26), orbit (n = 16) and skull-base (n = 14). All patients underwent operative resection of NCMH. A small 2014
case-series found DICER1 mutations in 6 NCMH patients, establishing a link to the DICER1 tumour spectrum.
Conclusions: NCMH is a rare cause of nasal masses in young children and adults. In light of the newly established link
between NCMH and DICER1 mutations surgeons should be vigilant for associated DICER1 tumours, as NCMH may be
the ‘herald tumour’ of this disease spectrum.
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Nasal chondromesenchymal hamartoma (NCMH) is a
very rare, benign tumour of the sinonasal tract. Forty-
seven cases have been reported in the English literature
and the vast majority of these presentations are in in-
fants and young children often below the age of one.
NCMHs have a mixed morphological structure com-
prised of predominantly mesenchymal and cartilaginous
components. NCMH patients present with symptoms
that are dependent on the location of the tumour in the
nasal cavity or paranasal sinuses and their compression
of local structures. These symptoms range from nasal
obstruction to visual impairment and facial and dental* Correspondence: katrina.a.mason@gmail.com
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creativecommons.org/publicdomain/zero/1.0/pain. To date there have only been 6 cases of adult pres-
entation of NCMH. Here we present the first systematic
review of NCMH cases published in the literature to as-
sess the patient demographics, presentation, manage-
ment and prognosis of NCMH alongside a new and
unusual case in an adult.Case report
A 49-year-old man was referred to our outpatient clinic
presenting with a small mass in his right nasal cavity.
The lump, which the patient first noticed 5 years ago,
had been growing insidiously over time and by the time
of presentation had become visible at the right anterior
naris. The patient did not complain of any symptoms
but sought consultation as his wife was concerned by
the cosmetic appearance of the mass.rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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the right side of the anterior nasal septum with approxi-
mately 0.5 cm attachment to the anterior cartilage of the
septum. The left and right nasal cavities were otherwise
unremarkable. Clinically, the mass had the appearance
of a papilloma confined to the nasal cavity with an at-
tachment to the septum only and therefore further im-
aging was not undertaken. The differential diagnoses
considered at the time of presentation were: nasal polyp,
squamous papilloma or inverted papilloma.
The patient subsequently underwent excisional biopsy
of the right nostril mass under general anaesthetic using
a circumferential subperichondrial incision with a small
margin. Intraoperatively, the mass had the macroscopic
appearance of a 0.5 cm × 2 cm × 2 cm calcified nodule.
Due to a small 0.5 cm base, subsequent healing was
achieved by secondary intention aided by the routine ap-
plication of topical antibacterial cream. Histopathological
analysis showed the nodule to contain cartilage and
aneurysmal bone covered in stratified squamous epithe-
lium with keratinisation (Figs. 1 and 2). Histopathological
diagnosis was made using a haematoxylin & eosin stain.
These findings were consistent with a diagnosis of a nasal
chondromesenchymal hamartoma.
The patient was followed up in clinic and was dis-
charged after 2 years having shown no signs of recurrence.
Furthermore, a telephone interview was conducted 4 years
post operation and the patient reported no recurrence of
the nasal mass. He confirmed that he had no post-
operative complications and was happy with the outcome
of the operation.Fig. 1 Nodule containing cartilage and aneurysmal bone and covered by s
haematoxylin & eosin stain)Methods
A systematic review was undertaken in accordance with
PRISMA guidelines [1]. No systematic review protocol
was used, however our systematic review methodology is
described below and a four-phase flow diagram is repre-
sented in Fig. 3. All published case-reports of NCMH
were included in the review. A PubMed search (MEDLINE)
(1975 to May Week 2, 2015) was carried out using the
following terms [(chondromesenchymal hamartoma) AND
(nasal OR sinus OR maxillary OR ethmoid OR sphenoid
OR frontal OR orbit OR cranial)]. An EMBASE search
(1975 to May Week 2, 2015) was carried out using a best
sensitivity-combination strategy. The PubMed search re-
sulted in 32 citations of which 24 were relevant, 6 were not
NCMH case-reports, one was a Chinese language case-
report, and one case was a duplicate case-report publication
[2]. An EMBASE search and a manual search through ref-
erences of relevant publications yielded 11 further relevant
citations. Of these only 6 were included in the analysis;
one case was found to have been a duplicate case report
[3, 4] and four other possible cases of NCMH were
found through publication citation search, but were la-
belled as “Mesenchymal chondrosarcoma” [5] “nasal
hamartoma” [6], “nasopharyngeal hamartoma” [7], and
“congenital mesenchymoma” [8], and were therefore
not included. Thirty-one publications that report 47
cases of NCMH were included in this systematic re-
view. Data was collected on patient demographics (age,
gender), laterality, size and site of NCMH, presentation,
co-morbidities, investigations, treatment and follow-up.
These were also the principle summary measures. Twotratified squamous epithelium with keratinisation (magnification ×25,
Fig. 2 Areas of osteoid formation (magnification ×200, haematoxylin & eosin stain)
8
Fig. 3 Four-phase flow diagram of systematic review in accordance with PRISMA guidelines * Two individual publications of single case-reports
were excluded from analysis as these had previously been published, Schultz et al. [2] and Kang et al. [3].** See Table 1
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through references of relevant publications, and extracted
the relevant data from the case-reports. Data was entered
into an Excel 2013 Microsoft Office™ database which was
used to carry out basic statistical analysis.
Results of systematic review
Forty-Eight NCMH patients (including our case) have
been reported in the English literature (Fig. 3). Most
cases presented in males; 33 male and 15 female, with a
male to female ratio of 2.2:1 ratio. The mean age was
9.6 years (range: 1 day–69 years). A large proportion of
these patients were aged 1 year or younger at presenta-
tion (n = 18) and only 8 adult patients (including our
case) have been described. Site of pathology was limited
to the nasal cavity only in 10 patients, and involved the
paranasal sinuses (maxillary, ethmoid, sphenoid) in 26
patients, the orbit in 16 patients, extending to the skull
base in 14 patients, had intracranial extension in 8 cases,
involved the nasopharynx in 3 patients and the orophar-
ynx in 2 patients (see Table 1).
Clinical presentations of NCMH patients included: nasal
congestion or obstruction (n = 17), nasal mass (n = 15),
eye signs (proptosis, hypotropia, enopthalmos, strabismus,
exotropia etc.) (n = 12), facial swelling (n = 8), headaches
or facial pain (n = 6), stertor or respiratory distress (n = 8),
ophthalmoplegia (n = 4), recurrent sinusitis (n = 4), rhinor-
rhoea (n = 3), otitis media (n = 2), epistaxis (n = 2), tooth-
ache (n = 1), hyposmia (n = 1), hydrocephalus (n = 1) and 4
patients were asymptomatic or had no signs and symp-
toms documented (see Table 1).
All patients underwent operative resection of NCMH
and the surgical approach was dependent on disease lo-
cation. One patient had pre-operative chemotherapy due
to initial misdiagnosis on biopsy as spindle cell sarcoma.
One patient had pre-operative embolization to reduce
operative blood loss. Follow up times were included for
24 patients, mean time for follow-up was 24 months,
(range 2–156 months). Eleven patients were found to
have persistent disease or disease recurrence on follow
up, seven required further surgery, three patients were
described as stable, and no further information was
given on the other patient. Li et al. described the first
and only reported case of malignant transformation of
NCMH [9].
Thirty-six patients had no documented past medical
problems. One adult patient had a history of multiple
vascular aneurysms. Eleven of the patients had been di-
agnosed with pleuropulmonary blastoma (PPB) prior to
NCMH detection. Of these 11 patients, 5 had other co-
morbidities including three with Sertoli-Lleydig cell ovarian
tumours, two with pulmonary cysts, one jejunal polyps,
one papillary thyroid carcinoma, one cystic nephroma and
one multinodular goitre.A potential weakness of this systematic review is the
possibility of reporting bias through publication bias
both within individual case reports and across the re-
view. This reporting bias is three-fold: firstly in the
incomplete publication of all the clinical aspects of the
case-reports by the original authors, for example not
reporting follow-up times or co-morbidities etc. Sec-
ondly it is possible that there have been cases of NCMH
that have not been reported in the literature and can
therefore not be included in the systematic review.
Thirdly the exclusion of case-reports of “Mesenchymal
chondrosarcoma” [5] “nasal hamartoma” [6], “nasopha-
ryngeal hamartoma” [7], and “congenital mesenchy-
moma” [8] alongside others, which are published prior
to the first description of NCMH by McDermot et al. in
1998, may have resulted in an underreporting of true
NCMH cases. However without being able to retrospect-
ively assess and re-classify the histology of these cases
we feel it is appropriate to have excluded them from our
analysis and conclusions. These sources of reporting
biases could potentially reduce the validity of conclu-
sions drawn in terms of not fully representing or captur-
ing all possible cases of NCMH.
Discussion
NCMHs are predominantly benign lesions that are lo-
cally destructive and because of their aggressive appear-
ance can be mistaken for a malignant tumour. However
NCMHs can be slow growing and therefore have a
delayed presentation. Histopathologically these lesions
are analogous to other mesenchymal hamartomas, and
consist of islands of chondroid tissue such as hyaline
cartilage, areas of calcification, and mesenchymal cellular
elements such as spindle cells and myxoid stroma.
McDermott et al. were the first to recognise NCMH as
a distinct clinic-pathological entity in 1998 when they
described a case series of seven patients with a tumefac-
tive process of the nasal passages and contiguous para-
nasal sinuses with a detectable mass in the nose [10]. In
this case series, six of the seven patients were infants
under the age of 3 months. As our systematic review
demonstrates NCMH predominantly presents in young
children and infants under the age of one, but there have
now been seven case reports, including ours, of adults
with NCMH up to the age of 69 [9, 11–14]. In 2013 the
first and only reported case of malignant transformation
of an NCMH was described in the literature [9].
In our case, the NCMH was initially thought to be a
papilloma confined to the nasal septal wall and therefore
further imaging was not undertaken prior to resection.
However pre-operative imaging of these lesions provides
valuable information regarding involvement of adjacent
structures such as the paranasal sinuses, orbit and intra-
cranial cavity. On computed tomography (CT) imaging,







Sex Side & Size Site Symptoms Co-morbidity Investigations Treatment Follow Up/
(1) McDermot,
1998 [10] USA




2 3 M F ND 1. Nasal cavity 1. Nasal Mass ND MRI Surgical excision No recurrence
at 2 years
2. Ethmoid Sinus 2. Otitis Media
3. Intracranial
extension












































8 3 M F Right Size:
3.5 × 7.5 × 2.5 cm
1. Nasal cavity 1. Epistaxis ND CT Surgical excision ND
























































11 0 D M Left Size: ND 1. Nasal cavity 1. Left facial
swelling










1. Sphenoid sinus 2. Left nasal mass






12 9 M M Right ND 1. Nasal cavity 1. Asymmetric
face
None stated CT MRI Surgical resection No recurrence at
9 months













14 1 Y M Left Size: ND 1. Nasal cavity 1. Proptosis of
left eye
Non stated CT Chemotherapy (VID) as
biopsy suggested
spindle cell sarcoma-
30 % reduction in




1.5 years near eye
but no further






















16 11 Y M Left Size: ND 1. Nasal cavity 1. Headaches
left sided



































Table 1 Summary table of systematic review of NCMH cases reported in the literature (Continued)
18 17 Y F ND Size: ND 1. Nasal cavity 1. Nasal
obstruction
None stated ND Surgical excision ND
2. Facial pain
19 25 Y M Bilateral
8 × 5 × 3.5 cm


































2. Oropharynx 2. Chronic
sinusitis




21 11 Y M Right Size: ND 1. Nasal cavity 1. Nasal
Obstruction





22 15 Y F Bilateral Size: ND 1. Nasal cavity 1. Nasal
obstruction













23 7 M M Right
3.2 × 1.4 cm

















24 12 Y M Left 1.5 cm 1. Nasal cavity 1. Nasal
obstruction
















25 12 M M Left
4 cm × 4.2 cm
1. Nasal cavity 1. Respiratory
distress


































26 19 M M Left 2.7 × 3.5 cm 1. Nasal cavity 1. Watery
rhinorrhoea
























- 7 Y * M Initially unilateral,
then bilateral
1. Sphenoid sinus 1. Nasal
Congestion
1. PPB type II–III Four resections
over 3 years
Followed up for 13
years with multiple
recurrences in first
3 years2. Left Nasal cavity 2. Nasal mass 2. Lung cysts




1. PPB Type II Surgical resection No recurrence at
51 months
2. Bony erosion of
posterior septum
















1. PPB Type III CT Surgical resection No recurrence at
21 months
28 11 Y M Right Size: ND 1. Nasal cavity 1. Nasal
obstruction







29 2.5 Y M Right Size: ND 1. Nasal cavity 1. Right eye
oculomotor
impairment









30 18 M* M Right
0.5 × 0.4 cm
1. Nasal cavity 1. Nasal
obstruction
None stated CT MRI Endoscopic surgical
resection
ND
















31 7 D F Right Size: ND 1. Nasal
cavity













































34 8 Y M ND 1. Sphenoid sinus 1. Frontal
Headache








35 14 Y M Left 5 cm ×
5.3 cm × 4 cm
1. Nasal cavity 1. Swelling and
pain to left face
None stated CT Subtotal maxillectomy,
removal or orbital floor,
removal of medial nasal
mucous membrane.
Reconstruction with
iliac crest bone block
No recurrence at
4 years




(25) Li Y, 2013
[12] China
36 40 Y F Bilateral Size: ND 1. Nasal Cavity 1. Nasal
Obstruction











37 23 Y M Left 3.2 × 2.5 cm 1. Naval cavity 1. Left
Lacrimal Sac
None stated ND Endoscopic surgical
excision
No recurrence at

















None stated CT MRI Surgery and care
undertaken in
another hospital










39 5 Y M Right 2.5 × 3.6 ×
4.3 cm
1. Nasal cavity 1. Recurrent
sinusitis


























40 6 W F Left 2.6 × 3.4 ×
3.9 cm
1. Nasal cavity 1. Nasal
obstruction










41 14 Y Size:
ND
M Bilateral 1. Bilateral nasal
cavities













- 7 Y** M Initially unilateral,
then bilateral
ND 1. Nasal Congestion 1. PPB Surgical resection Multiple recurrences
2. Lung cysts
- 15 Y** F Bilateral ND 1. Chronic Sinusitis 1. PPB Surgical resection No recurrence
2. Facial Pain 2. Sertoli-Leydig
Cell Ovarian
Tumour3. Nasal Congestion
- 10 Y** F Bilateral ND 1. Nasal congestion 1. PPB Surgical resection No recurrence
- 11 Y** M Right ND 1. Nasal Congestion 1. PPB Surgical resection No recurrence









44 8 Y M Bilateral Size: ND ND 1. Chronic Sinusitis 1. PPB ND Surgical resection No recurrence
45 6 Y F ND Size: ND ND ND 1. PPB ND Surgical resection No recurrence
2. Left cystic nephroma
3. Small bowel loop
46 21 Y F Right Size: ND ND 1. Nasal Congestion 1. PPB ND Surgical resection Recurrence
at 4 years



























47 12 Y M Right Size: ND 1. Nasal cavity 1. Nasal Obstruction None stated CT MRI Surgical excision No recurrence
at 5 months
2. Ethmoid sinus 2. Proptosis
3. Extension into
right orbit
3. Right facial pain
(32) Mason
2015 UK
48 49 Y M Right
0.5 × 2 × 2 cm
1. Nasal cavity 1. Nasal mass None stated None Surgical excision No recurrence at
4 years
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defined masses often with cystic components [15]. Mag-
netic resonance imaging (MRI) of NCMH demonstrates
a heterogeneous mass on T1 weighted images and T2
weighted images show the presence of cystic compo-
nents. MRI also has the advantage of superior tissue
characterisation and delineation of invasion of adjacent
structures in comparison to CT [16]. Due to rarity of
NCMH, even after thorough clinical and radiographic
examination NCMH can be misdiagnosed, and differen-
tial diagnoses include: inverted papilloma, aneurysmal
bone cysts or ossifying fibromas, nasoethmoidal ence-
phalocoele, chondrosarcoma, nasal lymphoma, nasal gli-
oma and rhabdomyosarcoma. Histopathological analysis
following surgical resection is therefore needed for ac-
curate diagnosis.
Patients with NCMH most commonly present with
symptoms of nasal obstruction, nasal mass, or eye signs,
which reflects the involvement of NCMH in the nasal
passages and orbit. Ophthalmic signs include signs of
globe displacement such as strabismus, extropia, hyper-
telorism, proptosis, enophthalmus and ophthlmoplegia,
direct results of the intra-ocular extension of NCMH or
ocular compression by NCMH [17–26]. There has also
been a report of a patient presenting with intra-oral
symptoms due to involvement of the oral cavity [4]. Pa-
tients can therefore present to otolaryngology, ophthal-
mology or maxillo-facial departments and doctors in
these specialties should be aware of this rare pathology.
In our case, the patient did not complain of any cranial,
ophthalmic or nasal symptoms but was aware of a slowly
enlarging nasal mass. This is most likely due to the rela-
tively small size of the tumour at the anterior nasal
septum which did not obstruct the nasal passage.
The aetiology of NCMH is thought to be due to an
underlying genetic predisposition therefore accounting for
the early presentation in the majority of cases. Priest et al.
and Stewart et al. investigated patients with both NCMH
and the rare paediatric dysembryonic sarcoma of the lung
and pleura: pleuropulmonary blastoma (PPB) [13, 27]. In
patients with NCMH and PPB Stewart et al. found germ-
line DICER1 mutations in 6 out of 8 evaluated patients,
and somatic DICER1 mutations in 2 out of those 6 pa-
tients with germline mutations [13]. This recent finding
has established genetic proof of NCMH tumour associ-
ation with DICER1 mutations and Stewart et al. therefore
feel that NCMH should be considered part of the DICER1
tumour spectrum. The DICER1 familial tumour suscepti-
bility syndrome confers an increased risk most commonly
for pleuropulmonary blastoma (PPB) but also ovarian sex
cord-stromal tumours; Sertoli-Leydig cell tumor [SLCT],
juvenile granulosa cell tumour [JGCT] and gynandroblas-
tomas. Less commonly the DICER1 tumour spectrum in-
cludes: cystic nephroma (CN), and thyroid gland neoplasia,multinodular goitres [MNG], adenomas, or differenti-
ated thyroid cancers. The rarest observed tumours in
this spectrum, alongside NCMHs, are ciliary body
medulloepithelioma (CBME), botryoid-type embryonal
rhabdomyosarcoma (ERMS) of the cervix or other sites,
renal sarcomas, pituitary blastomas, and pineoblasto-
mas [28]. Eleven patients in our systematic review had
previous PPB and five of these also had other DIECR1
tumours. Surgeons and physicians should therefore be
aware of these disease associations and should be vigi-
lant of a diagnosis of NCMH in patients presenting
with sino-nasal or orbital symptoms who have a history
of any of these tumours. Johnson et al. importantly also
point out that due to its location, NCMH is more likely
to present early in life than the other DICER1 tumours
[29]. Surgeons and physicians should therefore either
offer DICER1 mutation analysis if available, or ensure
long-term follow up of these patients and be vigilant
for associated tumours, as NCMH may be the ‘herald
tumour’ of this disease spectrum.
There are also cases in the literature of children, adoles-
cents and adults with NCMH who have had an asymp-
tomatic infancy [9, 11, 12, 14]. This may imply that there
are non-genetic components to NCMH pathogenesis. Al-
ternatively it may simply reflect the insidious growth of
the tumour or that some NCMH patients may only
exhibit the phenotype later in life. However as this is an
extremely rare pathology with only very recent formal as-
sociation with the DICER1 mutation, the majority of the
42 reported cases have not had formal DICER1 mutation
analysis. Therefore an association or lack thereof in the
non-tested cases cannot be inferred.
Successful management of NCMH entails complete re-
section in order to prevent recurrence. A complete exci-
sion however is not always technically feasible, especially
in cases of intracranial extension of NCMH. An incom-
plete resection poses the risk of recurrence as well as
the possibility of continued tumour growth and progres-
sive symptoms. Nine patients in this systematic review
were found to have disease recurrence, most likely from
incomplete surgical excision.
Conclusions
We present an unusual case of NCMH in an adult with-
out nasal obstructive symptoms due to the anatomical
location of the NCMH attached to the nasal septum. A
systematic review of the literature has highlighted that
presentation is mostly related to tumour location, with
nasal mass, nasal obstruction and ophthalmic signs be-
ing the most common forms of presentation. The major-
ity of patients presenting with NCMH are children and
infants below the age of one, but there have now been a
few adult cases of presentation. Surgical resection is the
treatment of choice with low recurrence rates in the
Mason et al. Journal of Otolaryngology - Head and Neck Surgery  (2015) 44:28 Page 13 of 14majority of cases. There has only been one reported
case of malignant transformation and NCMH is still
considered a benign tumour. NCMH’s association with
the DIECR1 mutation has very recently been estab-
lished and therefore in light of this any patient with a
DICER1-related tumour spectrum and new nasal or or-
bital symptoms should raise the suspicion of NCMH.
Furthermore surgeons should subsequently be vigilant
for associated DICER1 related tumours, as due to their
location NCMHs may be the ‘herald tumour’ for this
disease spectrum. This case and systematic review high-
lights the fact that NCMH can mimic other benign and
malignant lesions and that surgeons and physicians
should be aware of rare pathologies accounting for
nasal masses.
Consent
Written consent was obtained from the patient for pub-
lication of this case report and accompanying images. A
copy of the written consent is available for review by the
editor-in-chief of this journal.
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